India approves first Dengue vaccine Qdenga for ages 4-60, boosting fight against mosquito-borne disease


The growing threat to public health

Dengue has spread rapidly to many parts of the world in recent decades, driven by urbanization, climate change and changing weather patterns that have expanded the habitat of disease-carrying mosquitoes.

The World Health Organization estimates that nearly half of the global population is now at risk of dengue infection, with 100 million to 400 million cases occurring each year.

India has been among the hardest hit countries. Official figures show the country has recorded more than one million dengue cases and at least 1,500 deaths since 2021.

India may soon have a vaccine developed for dengue as well. Panacea Biotec’s vaccine candidate, DengiAll, has entered the final phase of clinical trials and, if approved, is expected to become one of the world’s first single-dose dengue vaccines.

The government said the approval of Qdenga reflects its commitment to providing timely access to safe and effective vaccines through a science-based regulatory framework.

Alex has been on the front lines of world titles for almost 30 years. A veteran editor, he is part newsroom veteran and part Globe correspondent. His credentials? He was part of the select group of journalists who covered Pope Francis’ historic visit to the United Arab Emirates – flying with the Pope himself. With 27 years on the ground in the Middle East, Alex is one of the most trusted voices in the region when it comes to deciphering politics and power games. He breaks down global issues into brilliant 60-second news stories – his morning reels are practically a daily ritual for audiences across the UAE. Sharp. Based. Quickly. Understanding. This is Alex at his best, bringing a steady editorial hand to every story he tells.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *